세계의 펩타이드 합성 시장 : 펩타이드 합성법 유형별, 화학 합성 유형별, 수탁 제조 기관 규모별, 주요 지역별-업계 동향 및 예측(-2035년)

Peptide Synthesis Market by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,778,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,886,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,971,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,423,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 펩타이드 합성 시장 규모는 2035년까지의 예측 기간 동안 5.5%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 현재의 28억 달러에서 2035년까지 51억 달러로 성장할 것으로 예측되고 있습니다.

신진 대사 안정성, 높은 친화력 및 생물학적 표적 특이성으로 인해 펩타이드 치료제는 지난 몇 년동안 유망한 수단으로 부상해 왔습니다. 80개가 넘는 펩타이드 프로그램이 전 세계의 다양한 규제 당국에 의해 승인되고 있는 것은 주목할 만합니다. 더불어 현재 630개 이상의 임상시험이 광범위한 질환의 치료를 위해 몇 가지 펩타이드 치료제를 평가하고 있습니다. 이것은, 이 영역에서 다양한 이해 관계자가 광범위한 개발 노력을 실시하고 있는 것을 나타내고 있습니다. 그러나 펩타이드 합성에는 몇 가지 과제가 있기 때문에 제약회사나 바이오테크놀로지 기업은 주요 업무를 외주하도록 되어 있습니다. 현재 75개 이상의 업계 기업이 제형 개발, 대량 생산, 분석 및 규제 지원, 프로세스 개발, 밸리데이션 배치, 패키징 및 라벨링, 프리포뮬레이션, 커스텀 펩타이드 합성 등 폭넓은 펩타이드 합성 서비스를 제공하고 있습니다.

의약품 개발 기업이 이러한 혁신적인 치료법에 더 많은 투자를 하고 있기 때문에 펩타이드 합성 시장은 더욱 확대될 것으로 예상됩니다. 또한 건전한 초기 단계의 파이프라인으로 인해 이 영역의 성장은 장기적으로도 계속될 것으로 예상됩니다.

본 보고서에서는 세계의 펩타이드 합성 시장에 대해 조사했으며, 시장 개요와 함께 펩타이드 합성법 유형별, 화학 합성 유형별, 수탁 제조 기관 규모별, 지역별 동향 및 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려 사항

제4장 주요 요약

제5장 서문

제6장 규제 상황

• 장의 개요
• 규제 시나리오 : 북미
• 규제 시나리오 : 유럽
• 규제 시나리오 : 아시아태평양
• 펩타이드 제조에 따른 과제

제7장 시장 상황

제8장 기업 경쟁력 분석

제9장 기업 프로파일

제10장 최근 동향 및 대처

제11장 임상시험 분석

제12장 지역별 능력 분석

제13장 수요 분석

제14장 용량 분석

제15장 파트너 후보 분석

제16장 제조 또는 구입의 의사결정의 틀

제17장 펩타이드 수탁 제조 조직의 총 소유 비용

제18장 세계의 펩타이드 치료제 수탁 API 제조 시장

제19장 펩타이드 치료제 수탁 API 제조 시장 : 펩타이드 합성법별

제20장 펩타이드 치료제 수탁 API 제조 시장 : 기업 규모별

제21장 펩타이드 치료제 수탁 API 제조 시장 : 지역별

제22장 SWOT 분석

제23장 결론

제24장 주요 인사이트

• 장의 개요
• Ascendia Pharmaceuticals
• Almac
• NUMAFERM
• Sekisui XenoTech
• Previtalica

제25장 부록 I : 표 형식 데이터

제26장 부록 II : 기업 및 단체 일람

AJY

영문 목차

영문목차

PEPTIDE SYNTHESIS MARKET: OVERVIEW

As per Roots Analysis, the global peptide synthesis market is estimated to grow from USD 2.8 billion in the current year to USD 5.1 billion by 2035, at a CAGR of 5.5% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Synthesis Method Used

• Chemical Synthesis Method
• Non-Chemical Synthesis Method

Type of Chemical Synthesis Method

• Liquid Phase Peptide Synthesis
• Solid Phase Peptide Synthesis
• Hybrid Phase Peptide Synthesis

Company (CMO) Size

• Small
• Mid-sized
• Large

Key Geographical Regions

• North America
• Europe
• Asia-Pacific and Rest of the World

PEPTIDE SYNTHESIS MARKET: GROWTH AND TRENDS

Owing to enhanced metabolic stability, higher affinity, and biological target specificity, peptide therapeutics have emerged as a promising modality in the past few years. It is worth highlighting that more than 80 peptide programs have been approved by different regulatory agencies across the globe. In addition, more than 630 clinical trials are currently evaluating several peptide therapeutics for the treatment of a wide range of diseases. This demonstrates the extensive development efforts being undertaken by various stakeholders in this domain. However, peptide synthesis is associated with several challenges that have prompted pharmaceutical and biotechnology companies to outsource key operations. At present, over 75 industry players are offering a wide range of peptide synthesis services, including formulation development, large scale production, analytical / regulatory support, process development, validation batches, packaging and labeling, pre-formulation and custom peptide synthesis.

As drug developers invest more in these innovative therapies, the peptide synthesis market is anticipated to expand further. Moreover, owing to the healthy early-stage pipeline, growth in this domain is expected to continue in the long term as well.

PEPTIDE SYNTHESIS MARKET: KEY INSIGHTS

The report delves into the current state of the peptide synthesis market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Currently, over 75 companies claim to offer peptide therapeutics contract API manufacturing services in order to cater to the rising demand for peptide API based drugs, across the globe.

2. The market landscape is highly fragmented, featuring the presence of both new entrants and established players in different geographical regions; close to 50% of such contract manufacturers are large companies.

3. Majority of players offer generic peptide API manufacturing using the chemical synthesis method; further, 60% of the peptide synthesis service providers offer API manufacturing with more than one type of peptide synthesis method.

4. In pursuit of gaining a competitive edge, peptide therapeutics contract API manufacturers are actively upgrading their existing capabilities and enhancing their service portfolios to establish a strong foothold in the domain.

5. The growing interest of developers in peptide-based therapeutics is evident from the rise in partnership activity; more than 30% of the deals were inked specifically for peptide API manufacturing.

6. In order to meet the rising demand for peptide APIs, service providers have made elaborate investments to expand their existing capacities and capabilities; this trend is most pronounced in Germany and the US.

7. In the last decade, over 600 clinical trials, enrolling close to 200 thousand patients suffering from a myriad of disease indications, have been registered across the globe to evaluate the efficacy of peptide-based drugs.

8. Since peptide-based drugs are being used progressively for the treatment of various diseases, the demand is indubitably rising and expected to grow at an annualized rate of over 7% in the near future.

9. The global installed peptide manufacturing capacity is spread across various geographies; majority of the capacity is installed in the production plants located in Asia-Pacific and Europe.

10. The projected opportunity for peptide therapeutics contract service providers is likely to be well distributed across different segments; currently, close to 40% of the contract manufacturing opportunity is captured by Europe.

PEPTIDE SYNTHESIS MARKET: KEY SEGMENTS

Currently, the Chemical Synthesis Method Occupies the Largest Share of the Peptide Synthesis Market

Based on the types of peptide synthesis methods, the global peptide synthesis market is segmented into chemical synthesis method and non-chemical synthesis method. It is worth highlighting that, owing to several benefits, such as flexibility, scalability, ease of implementation and cost-effectiveness, majority of the current peptide synthesis market is captured by the chemical synthesis method. This trend is likely to remain the same in the forthcoming years.

Currently, Solid Phase Peptide Synthesis Occupies the Largest Share of the Peptide Synthesis Market

Based on the type of chemical synthesis method, the global peptide synthesis market is segmented into solid phase peptide synthesis, liquid phase peptide synthesis, and hybrid phase peptide synthesis. It is worth highlighting that the solid phase peptide synthesis market is likely to witness substantial growth in the coming decade. This can be attributed to the fact that the solid phase peptide synthesis method offers numerous advantages, such as rapid formation of linear peptides, simple purification and cost-effectiveness.

Small Contract Manufacturers Segment is the Fastest Growing Segment of the Peptide Synthesis Market

Based on the company size, the peptide synthesis market is segmented into small, mid-sized, and large contract manufacturers. It is anticipated that small contract manufacturers are likely to grow at a higher CAGR in the forthcoming years.

Europe Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, and Asia-Pacific and the rest of the world. Majority of the share is expected to be captured by players based in Europe. It is worth highlighting that over the years, the market in Asia-Pacific and the rest of the world is expected to grow at a higher CAGR.

Example Players in the Peptide Synthesis Market

• AmbioPharm
• CPC Scientific
• Creative Peptides
• CSBio
• Bachem
• BCN Peptide
• CordenPharma
• Senn Chemicals
• PolyPeptide
• Auspep
• Chinese Peptide Company
• Hybio Pharmaceuticals
• Peptide Institute
• ScinoPharm

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Business Officer, Senior Director of Scientific Affairs and Technical Marketing, Ascendia Pharmaceuticals
• Vice President, Peptides, Almac
• Chief Financial Officer, NUMAFERM
• Senior Manager, Peptide Business Project Leader, Sekisui XenoTech
• Founder and Owner, Previtalica

PEPTIDE SYNTHESIS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the peptide synthesis market, focusing on key market segments, including [A] type of peptide synthesis method, [B] type of chemical synthesis, [C] contract manufacturing organization size and [D] key geographical regions.
• Market Landscape: A comprehensive evaluation of companies involved in peptide contract manufacturing, considering various parameters, such as [A] year of establishment, [B] year of entrance, [C] company (CMO) size (in terms of number of employees), [D] location of headquarters, [E] type of product, [F] type of API manufactured, [G] scale of operation, [H] type of services offered, [I] peptide synthesis method, [J] type of peptide modification, [K] type of purification technology used, [L] regulatory certifications and accreditations, [M] geographical presence and [N] location of peptide API manufacturing facilities.
• Company Competitiveness Analysis: A comprehensive competitive analysis of peptide contract manufacturers, examining factors such as [A] supplier strength, [B] company competitiveness and [C] number of peptide modification services offered.
• Company Profiles: In-depth profiles of key industry players engaged in the peptide therapeutics contract manufacturing market, focusing on [A] company overviews, [B] service portfolio, [C] location of production facilities and capabilities of service providers, [D] recent developments, and [E] an informed future outlook.
• Recent Developments and Initiatives: An analysis of recent trends, covering partnerships and collaborations, and expansion initiatives held in this domain.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various peptide therapeutics based on several relevant parameters, such as [A] trial registration year, [B] number of patients enrolled, [C] trial phase, [D] trial status, [E] study design, [F] type of sponsor / collaborator, [G] therapeutic area, [H] type of mechanism of action and clinical trial centers, [I] geography, and [J] enrolled patient population.
• Regional Capability Analysis: A detailed analysis on the capabilities of peptide synthesis companies in different regions, based on several relevant parameters, such as the number of CMOs, number of clinical sites, number of clinical trials, number of patients enrolled, number of peptide manufacturing facilities, demand for peptide therapeutics and installed capacity.
• Demand Analysis: Informed estimates of the annual commercial and clinical demand for peptide therapeutics based on several relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
• Capacity Analysis: The report provides an estimation of the global annual capacity of contract manufacturers in the peptide synthesis market. The analysis takes into consideration the distribution of available peptide production capacity across [A] companies of different sizes, [B] scale of operation, [C] location of manufacturing facility and [D] synthesis method.
• Likely Partner Analysis: An analysis highlighting potential strategic partners segregated based on the likelihood of entering into collaboration with peptide therapeutics developers. These players have been shortlisted based on several relevant parameters, such as [A] pipeline strength, [B] pipeline maturity, [C] year of establishment and [D] company size.
• Additional Insights: An insightful framework that emphasizes the key indicators and factors that need to be considered by developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
• Total Cost of Ownership: A region-wise, detailed analysis of the total cost of ownership for a peptide contract manufacturing service provider. It features an informed estimate of direct and indirect expenses taking into consideration 10 relevant parameters, over a span of 20 years.
• Regulatory Landscape: A discussion on general regulatory guidelines, highlighting the key differences across various geographies, including the US, Europe, Australia, China, India, Japan and South Korea. In addition, it provides details related to the various challenges, related to regulatory scrutiny, faced by peptide synthesis companies.
• SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution. Further, it includes a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall industry.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What is the current annual demand for peptide therapeutics?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Market Share Insights
• 1.3. Key Market Insights
• 1.4. Report Coverage
• 1.5. Key Questions Answered
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Considerations
  • 2.6.1. Demographics
  • 2.6.2. Economic Factors
  • 2.6.3. Government Regulations
  • 2.6.4. Supply Chain
  • 2.6.5. COVID Impact / Related Factors
  • 2.6.6. Market Access
  • 2.6.7. Healthcare Policies
  • 2.6.8. Industry Consolidation
• 2.7. Key Market Segmentations

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Overview of Peptides
  • 5.2.1. Structural Analysis of Peptides
  • 5.2.2. Classification of Peptides
  • 5.2.3. Peptide Synthesis
  • 5.2.4. Emerging Technologies for Peptide Synthesis
  • 5.2.5. Peptide Modification
    • 5.2.5.1. N-terminal Modification
    • 5.2.5.2. Internal Modification
    • 5.2.5.3. C-terminal Modification
    • 5.2.5.4. Other Modifications
  • 5.2.6. Peptide Purification
    • 5.2.6.1. Peptide Purity Guidelines
• 5.3. Overview of Contract Manufacturing
  • 5.3.1. Need for Outsourcing in the Peptide Manufacturing Industry
  • 5.3.2. General Considerations for Selecting a CMO Partner
  • 5.3.3. Advantages of Outsourcing Manufacturing Operations
  • 5.3.4. Risks and Challenges Associated with Outsourcing of Peptide API Manufacturing
• 5.4. Future Perspectives

6. REGULATORY LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Regulatory Scenario: North America
  • 6.2.1. Scenario in The US
    • 6.2.1.1. Overview
    • 6.2.1.2. General Guidelines for Peptide Manufacturing
• 6.3. Regulatory Scenario: Europe
  • 6.3.1. Scenario in Europe
    • 6.3.1.1. Overview
    • 6.3.1.2. General Guidelines
  • 6.3.2. Scenario in The UK
    • 6.3.2.1. Overview
    • 6.3.2.2. General Guidelines for Peptide Manufacturing
• 6.4. Regulatory Scenario: Asia-Pacific
  • 6.4.1. Overview
  • 6.4.2. Scenario in Australian
    • 6.4.2.1. General Guidelines for Peptide Manufacturing
  • 6.4.3. Scenario in Chinese
    • 6.4.3.1. General Guidelines for Peptide Manufacturing
    • 6.4.3.2. Tax-related Modifications in Chinese Pharmaceutical Sector
  • 6.4.4. Scenario in India
    • 6.4.4.1. General Guidelines for Peptide Manufacturing
    • 6.4.4.2. Tax-related Modifications in Indian Pharmaceutical Sector
  • 6.4.5. Scenario in Japan
    • 6.4.5.1. General Guidelines for Peptide Manufacturing
  • 6.4.6. Scenario in South Korea
    • 6.4.6.1. General Guidelines for Peptide Manufacturing
• 6.5. Challenges Associated with Peptide Manufacturing

7. MARKET LANDSCAPE

• 7.1 Chapter Overview
• 7.2 Peptide Therapeutics Contract API Manufacturing: Overall Market Landscape
  • 7.2.1. Analysis by Year of Establishment
  • 7.2.2. Analysis by Year of Entrance of Peptide API Contract Manufacturers
  • 7.2.3. Analysis by Company Size
  • 7.2.4. Analysis by Location of Headquarters
  • 7.2.5. Analysis by Type of Product
  • 7.2.6. Analysis by Type of API Manufactured
  • 7.2.7. Analysis by Scale of Operation
  • 7.2.8. Analysis by Type of Services Offered
  • 7.2.9. Analysis by Type of Peptide Synthesis Method
  • 7.2.10. Analysis by Type of Peptide Modification
  • 7.2.11. Analysis by Type of Purification Technology Used
  • 7.2.12. Analysis by Regulatory Certifications and Accreditations
  • 7.2.13. Analysis by Geographical Presence
  • 7.2.14. Analysis by Location of Peptide API Manufacturing Facilities
• 7.3. List of Custom Peptide Manufacturers

8. COMPANY COMPETITIVENSS ANALYSIS

• 8.1. Chapter Overview
• 8.2. Key Parameters
• 8.3. Methodology
• 8.4. Company Competitiveness Analysis
  • 8.4.1. Peptide Therapeutics Contract API Manufacturers with Low Manufacturing Capacity
  • 8.4.2. Peptide Therapeutics Contract API Manufacturers with Medium Manufacturing Capacity
  • 8.4.3. Peptide Therapeutics Contract API Manufacturers with High Manufacturing Capacity

9. COMPANY PROFILES

• 9.1 Chapter Overview
• 9.2. Peptide Therapeutics Contract API Manufacturers based in North America
  • 9.2.1. AmbioPharm
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Service Portfolio
    • 9.2.1.3. Manufacturing Facilities and Capabilities
    • 9.2.1.4. Recent Developments and Future Outlook
  • 9.2.2. CPC Scientific
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Service Portfolio
    • 9.2.2.3. Manufacturing Facilities and Capabilities
    • 9.2.2.4. Recent Developments and Future Outlook
  • 9.2.3. Creative Peptides
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Service Portfolio
    • 9.2.3.3. Manufacturing Facilities and Capabilities
    • 9.2.3.4. Recent Developments and Future Outlook
  • 9.2.4. CSBio
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Service Portfolio
    • 9.2.4.3. Manufacturing Facilities and Capabilities
    • 9.2.4.4. Recent Developments and Future Outlook
• 9.3. Peptide Therapeutics Contract API Manufacturers based in Europe
  • 9.3.1. Bachem
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Service Portfolio
    • 9.3.1.3. Manufacturing Facility and Capabilities
    • 9.3.1.4. Recent Developments and Future Outlook
  • 9.3.2. BCN Peptides
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Service Portfolio
    • 9.3.2.3. Manufacturing Facility and Capabilities
    • 9.3.2.4. Recent Development and Future Outlook
  • 9.3.3. CordenPharma
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Service Portfolio
    • 9.3.3.3. Manufacturing Facility and Capabilities
    • 9.3.3.4. Recent Developments and Future Outlook
  • 9.3.4. PolyPeptide
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Service Portfolio
    • 9.3.4.3. Manufacturing Facilities and Capabilities
    • 9.3.4.4. Recent Developments and Future Outlook
  • 9.3.5. Senn Chemicals
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Service Portfolio
    • 9.3.5.3. Manufacturing Facilities and Capabilities
    • 9.3.5.4. Recent Developments and Future Outlook
• 9.4. Peptide Therapeutics Contract API Manufacturers based in Asia-Pacific
  • 9.4.1. Auspep
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Service Portfolio
    • 9.4.1.3. Manufacturing Facilities and Capabilities
    • 9.4.1.4. Recent Developments and Future Outlook
  • 9.4.2. Chinese Peptide
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Service Portfolio
    • 9.4.2.3. Manufacturing Facilities and Capabilities
    • 9.4.2.4. Recent Developments and Future Outlook
  • 9.4.3. Hybio Pharmaceutical
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Service Portfolio
    • 9.4.3.3. Manufacturing Facilities and Capabilities
    • 9.4.3.4. Recent Developments and Future Outlook
  • 9.4.4. Peptide Institute
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Service Portfolio
    • 9.4.4.3. Manufacturing Facilities and Capabilities
    • 9.4.4.4. Recent Developments and Future Outlook
  • 9.4.5. ScinoPharm
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Service Portfolio
    • 9.4.5.3. Manufacturing Facilities and Capabilities
    • 9.4.5.4. Recent Developments and Future Outlook

10. RECENT DEVELOPMENTS AND INITIATIVES

• 10.1. Chapter Overview
• 10.2. Partnerships and Collaborations
  • 10.2.1. Partnerships Models
  • 10.2.2. List of Partnerships and Collaborations
  • 10.2.3. Analysis by Year of Partnership
  • 10.2.4. Analysis by Type of Partnership
  • 10.2.5. Analysis by Year and Type of Partnership
  • 10.2.6. Analysis by Company Size and Type of Partnership
  • 10.2.7. Analysis by Scale of Operation
  • 10.2.8. Analysis by Scale of Operation and Type of Partnership
  • 10.2.9. Analysis by Green Chemistry Integration
  • 10.2.10. Most Active Players: Analysis by Number of Partnerships
  • 10.2.11. Analysis by Geography
    • 10.2.11.1. Intercontinental and Intracontinental Agreements
    • 10.2.11.2. Local and International Agreements
• 10.3. Recent Expansion Models
  • 10.3.1. Expansion Models
  • 10.3.2 List of Recent Expansions
  • 10.3.3. Analysis by Year of Expansion
  • 10.3.4. Analysis by Type of Expansion
  • 10.3.5. Analysis by Year and Type of Expansion
  • 10.3.6. Analysis by Location of Expanded Facility (Region)
  • 10.3.7. Analysis by Location of Expanded Facility (Country)
  • 10.3.8. Recent Expansions: Analysis by Location of Expanded Facility and Type of Expansion
  • 10.3.9. Most Active Players: Analysis by Number of Expansions
  • 10.3.10. Recent Expansions: Analysis by Geography (Country)
  • 10.3.11. Recent Expansions: List of Planned Expansions
• 10.4. Emerging Peptide Synthesis Technologies
  • 10.4.1. Chemo-Enzymatic Peptide Synthesis Technology
  • 10.4.2. Continuous Flow Technology
  • 10.4.3. Green Chemistry

11. CLINICAL TRIAL ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Peptide Therapeutics: Clinical Trials Analysis
  • 11.3.1. Analysis by Trial Registration Year
  • 11.3.2. Analysis by Number of Patients Enrolled
  • 11.3.3. Analysis by Trial Phase
  • 11.3.4. Analysis by Trial Registration Year and Trial Phase
  • 11.3.5. Analysis by Trial Phase and Patients Enrolled
  • 11.3.6. Analysis by Trial Status
  • 11.3.7. Analysis by Trial Registration Year and Trial Status
  • 11.3.8. Analysis by Therapeutic Area
  • 11.3.9. Analysis by Mechanism of Action
  • 11.3.10. Analysis by Trial Registration Year and Mechanism of Action
  • 11.3.11. Analysis by Type of Sponsor / Collaborator
  • 11.3.12. Analysis by Study Design
    • 11.3.12.1. Analysis by Type of Patient Allocation Model Used
    • 11.3.12.2. Analysis by Type of Trial Masking Adopted
    • 11.3.12.3. Analysis by Type of Intervention
    • 11.3.12.4. Analysis by Trial Purpose
  • 11.3.13. Most Active Players: Analysis by Number of Clinical Trials
  • 11.3.14. Analysis by Geography
    • 11.3.14.1. Analysis of Clinical Trials by Geography
    • 11.3.14.2. Analysis of Clinical Trials by Geography and Trial Status
    • 11.3.14.3. Analysis of Clinical Trials by Geography and Therapeutic Area
    • 11.3.14.4. Analysis of Patients Enrolled by Geography
    • 11.3.14.5. Analysis of Patients Enrolled by Geography and Trial Status

12. REGIONAL CAPABILITY ANALYSIS

• 12.1. Chapter Overview
• 12.2. Key Assumptions and Methodology
• 12.3. Overall Landscape of Peptide Therapeutics Contract API Manufacturing Facilities
• 12.4. Peptide Therapeutics Contract API Manufacturing Capability in North America
• 12.5. Peptide Therapeutics Contract API Manufacturing Capability in Europe
• 12.6. Peptide Therapeutics Contract API Manufacturing Capability in Asia-Pacific

13. DEMAND ANALYSIS

• 13.1. Chapter Overview
• 13.2. Assumptions and Methodology
• 13.3. Peptide Therapeutics Contract API Manufacturing: Overall Annual Demand
  • 13.3.1. Peptide Therapeutics Contract API Manufacturing: Clinical Demand
    • 13.3.1.1. Clinical Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by Phase of Development
  • 13.3.2. Peptide Therapeutics Contract API Manufacturing: Commercial Outsourced Demand
    • 13.3.2.1. Commercial Demand for Peptide Therapeutics Contract API Manufacturing: Analysis by GLP-1 Mechanism of Action
  • 13.3.3. Peptide Therapeutics Contract API Manufacturing: Analysis by Type of Peptide API Synthesis
  • 13.3.4. Peptide Therapeutics Contract API Manufacturing: Analysis by Geography

14. CAPACITY ANALYSIS

• 14.1. Chapter Overview
• 14.2. Key Assumptions and Methodology
• 14.3. Peptide Therapeutics Contract API Manufacturing: Global Installed Capacity
  • 14.3.1. Analysis by Company Size
  • 14.3.2. Analysis by Scale of Operation
  • 14.3.3. Analysis by Location of Manufacturing Facility
  • 14.3.4. Analysis by Company Size and Location of Manufacturing Facility
  • 14.3.5 Analysis by Chemical Synthesis Method
• 14.4. Concluding Remarks

15. LIKELY PARTNERS ANLAYSIS

• 15.1. Chapter Overview
• 15.2. Scoring Criteria and Key Assumptions
• 15.3. Scope and Methodology
• 15.4. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in North America
  • 15.4.1. Most Likely Partners
  • 15.4.2. Likely Partners
  • 15.4.3. Least Likely Partners
• 15.5. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Europe
  • 15.5.1. Most Likely Partners
  • 15.5.2. Likely Partners
  • 15.5.3. Least Likely Partners
• 15.6. Potential Strategic Partners for Peptide Therapeutics Contract Manufacturers in Asia Pacific and Rest of the World
  • 15.6.1. Most Likely Partners
  • 15.6.2. Likely Partners
  • 15.6.3. Least Likely Partners

16. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

• 16.1. Chapter Overview
• 16.2. Assumptions and Parameter Definitions
• 16.3. Make versus Buy Decision Making Framework
  • 16.3.1. Scenario 1
  • 16.3.2. Scenario 2
  • 16.3.3. Scenario 3
  • 16.3.4. Scenario 4
• 16.4. Concluding Remarks

17. TOTAL COST OF OWNERSHIP FOR PEPTIDE CONTRACT MANUFACTURING ORGANIZATIONS

• 17.1. Chapter Overview
• 17.2. Assumptions and Methodology
• 17.3. Key Parameters
• 17.4. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization, Y0-Y20
• 17.5. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX And OPEX, Y0 and Y20
  • 17.5.1. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by CAPEX, Y0
  • 17.5.2. Total Cost of Ownership for Peptide Therapeutics Contract API Manufacturing Organization: Analysis by OPEX, Y1-Y20

18. GLOBAL PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Global Peptide Therapeutics Contract API Manufacturing Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 18.3.1. Scenario Analysis
    • 18.3.1.1. Conservative Scenario
    • 18.3.1.2. Optimistic Scenario
• 18.4. Key Market Segmentations

19. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY TYPE OF PEPTIDE SYNTHESIS METHOD

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Type of Peptide Synthesis Method, Current Year and 2035
  • 19.3.1. Non-chemical Synthesis Method Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.3.2. Chemical Synthesis Method Market: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.3.2.1 Liquid Phase Synthesis: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.3.2.2 Solid Phase Synthesis: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.3.2.3 Hybrid Phase Synthesis: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY COMPANY SIZE

• 20.1. Chapter Overview
• 20.2. Key Assumptions and Methodology
• 20.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Company Size, Current Year and 2035
  • 20.3.1. Small Company: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.2. Mid-sized Company: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3.3. Large Company: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
• 20.4. Data Triangulation and Validation

21. PEPTIDE THERAPEUTICS CONTRACT API MANUFACTURING MARKET, BY GEOGRAPHY

• 21.1. Chapter Overview
• 21.2. Assumptions and Methodology
• 21.3. Peptide Therapeutics Contract API Manufacturing Market: Distribution by Geography, Current Year and 2035
  • 21.3.1. Peptide Therapeutics Contract API Manufacturing Market in North America: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.3.1.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in North America
    • 21.3.1.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in North America
    • 21.3.1.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in North America
    • 21.3.1.4. Peptide Therapeutics Contract API Manufacturing Market in North America for Chemical Synthesis Method
    • 21.3.1.5. Peptide Therapeutics Contract API Manufacturing Market in North America for Non- Chemical Synthesis Method
  • 21.3.2. Peptide Therapeutics Contract API Manufacturing Market in Europe: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.3.2.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Europe
    • 21.3.2.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Europe
    • 21.3.2.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Europe
    • 21.3.2.4. Peptide Therapeutics Contract API Manufacturing Market in Europe for Chemical Synthesis Method
    • 21.3.2.5. Peptide Therapeutics Contract API Manufacturing Market in Europe for Non-Chemical Synthesis Method
  • 21.3.3. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World: Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.3.3.1. Peptide Therapeutics Contract API Manufacturing Market for Small Companies in Asia- Pacific and Rest of the World
    • 21.3.3.2. Peptide Therapeutics Contract API Manufacturing Market for Mid-sized Companies in Asia- Pacific and Rest of the World
    • 21.3.3.3. Peptide Therapeutics Contract API Manufacturing Market for Large and Very Large Companies in Asia-Pacific and Rest of the World
    • 21.3.3.4. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Chemical Synthesis Method
    • 21.3.3.5. Peptide Therapeutics Contract API Manufacturing Market in Asia-Pacific and Rest of the World for Non-Chemical Synthesis Method
• 21.4. Data Triangulation and Validation

22. SWOT ANALYSIS

• 22.1. Chapter Overview
• 22.2. Strengths
• 22.3. Weaknesses
• 22.4. Opportunities
• 22.5. Threats
• 22.6. Comparison of SWOT Factors
• 22.7. Concluding Remarks

23. CONCLUSION

24. EXECUTIVE INSIGHTS

• 24.1. Chapter Overview
• 24.2. Ascendia Pharmaceuticals
  • 24.2.1. Company Snapshot
  • 24.2.2. Interview Transcript: Chief Business Officer, and Senior Director of Scientific Affairs and Technical Marketing
• 24.3. Almac
  • 24.3.1. Company Snapshot
  • 24.3.2. Interview Transcript: Vice President, Peptides
• 24.4. NUMAFERM
  • 24.4.1. Company Snapshot
  • 24.4.2. Interview Transcript: Chief Financial Officer
• 24.5. Sekisui XenoTech
  • 24.5.1. Company Snapshot
  • 24.5.2. Interview Transcript: Senior Manager, Peptide Business Project Leader
• 24.6. Previtalica
  • 24.6.1. Company Snapshot
  • 24.6.2. Interview Transcript: Founder and Owner

25. APPENDIX I: TABULATED DATA

26. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

관련자료